英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
874774查看　874774　在百度字典中的解释百度英翻中〔查看〕
874774查看　874774　在Google字典中的解释Google英翻中〔查看〕
874774查看　874774　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • Libtayo (cemiplimab) vs Krazati (adagrasib) - Everyone. org
    Libtayo (cemiplimab) vs Krazati (adagrasib) Libtayo (cemiplimab) and Krazati (adagrasib) are both used in the treatment of certain types of cancer, but they have different mechanisms of action and indications
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • Libtayo more favorable than Keytruda for first-line . . .
    The FDA approved Libtayo in 2022 as a first-line treatment for advanced NSCLC, in combination with chemotherapy However, it has been unclear whether this new combination treatment could outperform Keytruda plus chemotherapy from a cost-effectiveness standpoint
  • Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced non-small cell lung cancer (NSCLC) Review Important Safety Info Full Prescribing Information including Med Guide
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S . . . - BioSpace
    Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced non-small cell lung cancer (NSCLC) and advanced cervical cancer
  • ClinicalTrials. gov
    Study record managers: refer to the Data Element Definitions if submitting registration or results information
  • Cemiplimab: Side Effects, Uses, Dosage, Interactions, Warnings
    Cemiplimab is a cancer medicine that helps your immune system fight certain cancers What it treats Advanced or hard-to-treat: Some skin cancers (certain squamous cell and basal cell skin cancers) Some types of lung cancer (non–small cell lung cancer) Cemiplimab is available under the following different brand names: Libtayo, cemiplimab-rwlc
  • FDA Approvals in Oncology: October-December 2025 | Blog | AACR
    In the last quarter of 2025, the FDA announced 20 approvals in oncology, including new treatments for lung cancer, multiple myeloma, and more
  • Libtayo (cemiplimab-rwlc): Uses, Side Effects . . . - WebMD
    Libtayo (cemiplimab-rwlc) is commonly used to treat certain types of cancer It is used to treat certain types of skin cancers, including cutaneous squamous cell carcinoma (CSCC) and basal cell





中文字典-英文字典  2005-2009